Menu

Albireo to Present at 37th Annual Cowen and Company Health Care Conference

March 1, 2017

BOSTON — March 1, 2017 — Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that Ron Cooper, President and Chief Executive Officer, will make a corporate presentation and provide a business update at the 37th Annual Cowen and Company Health Care Conference at the Boston Marriott Copley Place on Wednesday, March 8, 2017, at 8:00 a.m. ET.

A live audio webcast of the presentation will be accessible from the Investors page of Albireo’s website, ir.albireopharma.com. To ensure a timely connection to the webcast, it is recommended that users register at least 15 minutes prior to the scheduled start time. An archived version of the webcast will be available for replay on the Events & Presentations section of the Investors page of Albireo’s website for at least two weeks following the event.

For more information about the conference, visit: www.cowen.com/conferences/upcoming-conferences.

About Albireo 

Albireo is a clinical-stage biopharmaceutical company focused through its operating subsidiary on the development of novel bile acid modulators to treat orphan pediatric liver diseases and other liver and gastrointestinal diseases and disorders. Albireo’s clinical pipeline includes two Phase 2 product candidates and one Phase 3 product candidate. Albireo was spun out from AstraZeneca in 2008.

Albireo Pharma is located in Boston, Massachusetts, and its key operating subsidiary, Albireo AB, is located in Gothenburg, Sweden. For more information on Albireo, please visit www.albireopharma.com.

###

Investor Contact:

Hans Vitzthum

LifeSci Advisors, LLC.

212-915-2568

 

Media Contact:

Heather Anderson

6 Degrees

980-938-0260

handerson@6degreespr.com

 

Source: Albireo Pharma, Inc.

Albireo Homepage